Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Urtė Fultinavičiūtė

Reporter

London, UK

Urtė has previously worked as a Healthcare Reporter at GlobalData Media, primarily writing for Clinical Trials Arena. She mostly focused on clinical trial data management, strategy, and regulatory updates as well as clinical trial data readouts and exclusive interviews with C-level pharma and biotech executives. Urtė holds an MA in International Journalism from City, University of London.

Latest From Urtė Fultinavičiūtė

Cosette Launches First US Generic To AbbVie’s Rectiv

Approval of Cosette’s first US generic to Rectiv came with a six-month exclusivity as the originator drug had “inadequate generic competition,” but the company has 75 days to enter the market.

Approvals Generic Drugs

FDA’s New PSG Batch Features GSK’s Inhalers

In its latest batch of product-specific guidances, the FDA released multiple new and revised guidances on inhalers, including several on GSK’s products such as Relenza and the Ellipta trio.

United States Guidance Documents

Sandoz Enters Canada With First Denosumab Biosimilar

Sandoz has truly established its position as the frontrunner in the denosumab race after a Canadian approval, but the path to the US market has been hindered by a lawsuit from the originator Amgen.

Biosimilars Approvals

Outlook Sees Finish Line For Ophthalmic Bevacizumab

While a European decision is just around the corner, Outlook Therapeutics has more work to do in the US to convince the FDA about its bevacizumab product.

Biologics Biosimilars

AAM Applauds FTC-HHS Probe Into Generic Drug Shortages

As two US governmental agencies launch an investigation into the potential causes of drug shortages, AAM says the generics industry faces “unprecedented threats.”

United States Generic Drugs

Biogen’s Biosimilars Sales Rise, But Future Still Unknown

Biogen has yet again hinted about “strategic alternatives” for its biosimilars business albeit with no clear future plans, while its branded multiple sclerosis portfolio fights off generic and biosimilar competitors.

Biosimilars Strategy
See All
UsernamePublicRestriction

Register